The effect of rhinitis or a topical decongestant on nafarelin absorption by the nasal mucosa has not yet been determined. Normal function is usually restored within 4 to 8 weeks after treatment is discontinued. Diagnostic tests of pituitary-gonadal function conducted during the treatment and within 8 weeks after discontinuation of nafarelin therapy may therefore be misleading. All newborns were normal except for one male baby who had hydrocele. The serum concentration of gonadotropins and estradiol returned promptly to normal after cessation of therapy.
Rodents are particularly sensitive to hormonal stimulation when tested for tumorigenicity.
No evidence of tumorigenicity has been reported in monkeys or man. No indication of a mutagenic potential for nafarelin has been reported. As would be expected with a drug which lowers serum estradiol levels, the most frequently reported adverse reactions were those related to hypoestrogenism. There was little, if any, decrease in the mineral content in compact bone of the distal radius and second metacarpal. Use of nafarelin for longer than the recommended 6 months or in the presence of other known risk factors for decreased bone mineral content may cause additional bone loss.